<DOC>
	<DOCNO>NCT00127478</DOCNO>
	<brief_summary>The primary purpose study evaluate long-term safety tolerability atrasentan 10 mg men hormone refractory prostate cancer .</brief_summary>
	<brief_title>A Long Term Safety Study With Atrasentan</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>Greater equal 18 year , inclusive ; Subject currently active atrasentan clinical study OR histologically cytologically document diagnosis prostate adenocarcinoma consider hormone refractory ; Karnofsky Performance Score great equal 60 ; Adequate hematologic function liver function test ; No New York Heart Association ( NYHA ) class great equal 2 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
	<keyword>Adenocarcinoma Prostate</keyword>
</DOC>